Some Forms of Birth Control May Increase Risk of Brain Tumors in Women: Study

Depo-Provera birth control injections, which are often used among poor and vulnerable populations of women, were linked to the highest risk of brain tumors.

Taking certain forms of birth control and hormone therapy may increase a woman’s risk of developing brain tumors by a factor of five, according to the findings of a new study.

Researchers warn that women who take synthetic progestogen hormone products, including the popular injected contraceptive Depo-Provera, may be more likely to develop meningioma, which can create pressure on the brain and often requires surgical removal. The findings were published on March 27 in the journal The BMJ.

Meningiomas are a type of rare brain tumor that occurs only about 10 times per hundred thousand person-years. They typically are not cancerous and are slow growing, but account for 40% of central nervous system tumors. Even when not cancerous, they can put pressure on the brain, requiring surgical removal or other interventions to decompress the tissue.

Studies have found that this type of brain tumor contains progesterone receptors, which indicates there may be a link between the increased risk of this brain tumor and female sex hormones.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

In this latest study, French researchers used data from more than 108,000 women in the French National Health Data System. They examined information from 18,000 women living in France who underwent brain surgery for meningioma between 2009 and 2018. Each woman was matched with five control patients for comparison.

Researchers compared different types of synthetic progestogen hormones and different delivery methods, including oral, vaginal, and injection.

The data indicated taking synthetic progestogens long-term, for more than one year, increases a person’s risk of developing brain tumors. Different types of progestogen hormones increase a woman’s risk of developing the rare brain tumor by different amounts.

The most pronounced brain tumor risk was linked to side effects of Depo-Provera, a commonly used birth control injection, which increased the risk by 5.6 times, the researchers determined. Roughly 74 million women around the world use Depo-Provera for birth control, suggesting that millions of women may face an increased brain tumor risk.

However, other types of progestogen hormones were also linked to an increased risk. Colprone, a hormone replacement therapy (HRT) often used during menopause, was linked to a four times higher risk. Sugestone, an oral pill used for both birth control and hormone replacement during menopause, increased the risk of developing this type of brain tumor by 2.7-fold, according to the data.

Other progestogen-based products, like Mirena and Kyleena intrauterine devices (IUDs) used for birth control, did not increase the risk of brain tumors, and neither did Climaston and Femaston, vaginal hormones widely used to treat infertility, irregular menstrual cycles, polycystic ovarian syndrome (PCOS), and used after miscarriage, the researchers determined.

Progestogen Brain Tumor Risks

Among women not taking hormones, roughly four in every thousand women will develop this type of brain tumor by the age of 80. Using birth control like Depo-Provera increases that risk to 20 in every thousand women, researchers warned.

Other studies have indicated the size of these brain tumors may increase during pregnancy, and then decrease after a woman gives birth. This highlights the potential link between female hormones and tumor growth, and may explain why taking some types of progestogen hormones appears to increase the risk.

“Although the risk of meningioma was already known for three progestogens, this study is the first to assess the risk associated with progestogens that are much more widely used for multiple indications, such as contraception,” the researchers concluded. “Studies from countries with a broader use of (Depo-Provera), which, furthermore, is often administered to vulnerable populations, are urgently needed to gain a better understanding of its dose-response association.”

Image Credit: |

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

AT&T Data Breach Class Action Claims Telecom Giant
AT&T Data Breach Class Action Claims Telecom Giant "Disregarded" Customer Financial Safety (Posted yesterday)

A Missouri woman is one of the latest person to file an class action claim over the AT&T data breach, after the telecom company admitted that hackers stole millions of customers' personal information and sold it on the internet.

Plaintiffs Oppose Phased Discovery Over Suboxone Tooth Decay Risks in MDL
Plaintiffs Oppose Phased Discovery Over Suboxone Tooth Decay Risks in MDL (Posted 2 days ago)

Plaintiffs say a federal judge should not waste time on a phased discovery plan requiring them to first prove Suboxone strips can cause tooth decay, saying the science is obvious and such a plan could delay resolution of hundreds of product liability lawsuits.